- Home
- / MegaPro Biomedical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
MegaPro Biomedical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
NT$16.9
2024-10-29
Market Capitalization
NT$1.1 B
2024-10-29
CreditSafe Score
?
Score changed on Jun 20, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| TWD | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 7.4M | 18.0K | 14.0K | |||
| Gross profit | 7.4M | 11.3M | 226.0K | 9.4M | 5.5M | 727.0K |
| Gross profit margin, % | 100.1% | 52416.7% | 39457.1% | |||
| Operating expense total | 150.7M | 93.4M | 108.2M | 123.9M | 163.0M | 104.5M |
| Depreciation and amortization | 6.0M | 7.5M | 13.6M | 16.6M | 17.2M | 15.1M |
| EBITDA | (143.3M) | (82.1M) | (108.0M) | (114.8M) | (157.5M) | (103.8M) |
| EBITDA margin, % | -1929.0% | -637505.6% | -1124814.3% | |||
| EBIT | (149.3M) | (89.6M) | (121.3M) | (131.4M) | (175.7M) | (119.2M) |
| EBIT margin, % | -2010.1% | -729755.6% | -1255064.2% | |||
| Interest income | 2.3M | 1.1M | 2.6M | 5.1M | 5.6M | 2.8M |
| Interest expense | 371.0K | 295.0K | 451.0K | 138.0K | ||
| Pre tax profit | (148.9M) | (89.2M) | (111.3M) | (127.6M) | (164.0M) | (119.1M) |
| Income tax expense | 436.0K | (4.0K) | ||||
| Net Income | (148.9M) | (89.2M) | (111.7M) | (127.5M) | (164.0M) | (119.1M) |